聚乙二醇干扰素α-2b 联合利巴韦林治疗 HCV 基因型 4 感染。
Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection.
机构信息
Yassin Abdel Ghaffar Charity Center for Liver Disease and Research, Menoufia, Egypt.
出版信息
Indian J Pediatr. 2009 Sep;76(9):895-8. doi: 10.1007/s12098-009-0187-x. Epub 2009 Nov 4.
OBJECTIVE
To evaluate safety and efficacy of Peg-INF combined with ribavirin for genotype 4 infected children.
METHODS
Seven children were included, five were infected parentrally, One vertically and one had both exposures. Clinical and laboratory evaluation were undertaken as well as quantitative PCR for HCV RNA before therapy at, 12, 24 and 52 weeks during treatment and one year after therapy. Liver biopsy was performed before and at the end of therapy. Four children had low and three had moderate viremia.
RESULTS
At twelve weeks, two children (28.6%) lost viremia. Another child lost viremia at 52 weeks. ETR was 42.9%. During follow up one relapsed, thus SVR was 28.6%. Children with SVR were the youngest, their mean duration of infection was 4.5 vs 12.7 years in the others. Side effects of both INF & ribavirin was mild, required no reduction in doses.
CONCLUSION
Combination therapy of peg interferon-alpha with ribavirin is well tolerated in children and adolescents studied.
目的
评估 Peg-INF 联合利巴韦林治疗基因 4 型感染儿童的安全性和疗效。
方法
纳入 7 名儿童，5 名经母婴传播感染，1 名垂直传播感染，1 名两者皆有。治疗前、治疗 12、24、52 周及治疗结束后 1 年均进行临床和实验室评估以及 HCV RNA 定量 PCR。肝活检在治疗前后进行。4 名儿童病毒载量较低，3 名儿童病毒载量中等。
结果
治疗 12 周时，2 名儿童（28.6%）病毒血症消失。另一名儿童在 52 周时病毒血症消失。ETR 为 42.9%。随访期间 1 名患儿复发，因此 SVR 为 28.6%。SVR 患儿年龄最小，其平均感染持续时间为 4.5 年，而其他患儿为 12.7 年。INF 和利巴韦林的副作用均较轻，无需减少剂量。
结论
聚乙二醇干扰素-α联合利巴韦林治疗在研究中的儿童和青少年中具有良好的耐受性。
Zotero 插件